Results 1 to 10 of about 5,702,443 (273)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma [PDF]

Blood Advances
: Elotuzumab is a monoclonal antibody targeting signaling lymphocyte activation molecule F7 on plasma and natural killer cells, which enhances the activity of lenalidomide, pomalidomide, and bortezomib in multiple myeloma (MM). The OPTIMISMM study showed
Andrew J. Yee, Jacob P. Laubach, Erica L. Campagnaro, Brea C. Lipe, Omar Nadeem, Robb S. Friedman, Craig E. Cole, Elizabeth K. O’Donnell, Giada Bianchi, Andrew R. Branagan, Robert L. Schlossman, Samantha J. Shapiro, Cynthia C. Harrington, Jill N. Burke, Marilyn T. Gammon, Kathleen J. Lively, Cassandra A. Reimonn, Danielle X. Andrade, Robert Redd, Jens G. Lohr, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje   +22 more
doaj   +2 more sources

Multiple myeloma [PDF]

Cancer Imaging, 2004
Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the current status and highlights how an understanding of both is necessary for optimum management.
S. Vincent Rajkumar, Robert A. Kyle
  +14 more sources

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma

Cells, 2022
Immunological tolerance of myeloma cells represents a critical obstacle in achieving long-term disease-free survival for multiple myeloma (MM) patients.
Megan Johnstone, Delaney Vinaixa, Marcello Turi, Eugenio Morelli, Kenneth Carl Anderson, Annamaria Gulla   +5 more
doaj   +1 more source

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2021
BACKGROUND Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and ...
N. Munshi, L. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Yi Lin, D. Siegel, A. Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A. Rambaldi, D. Reece, F. Petrocca, M. Massaro, Jamie N. Connarn, S. Kaiser, P. Patel, Liping Huang, T. Campbell, K. Hege, J. San-Miguel   +27 more
semanticscholar   +1 more source

Teclistamab in Relapsed or Refractory Multiple Myeloma.

New England Journal of Medicine, 2022
BACKGROUND Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells.
P. Moreau, A. Garfall, N. V. D. van de Donk, H. Nahi, J. San-Miguel, A. Oriol, A. Nooka, T. Martin, L. Rosiñol, A. Chari, L. Karlin, L. Benboubker, M. Mateos, N. Bahlis, R. Popat, B. Besemer, J. Martínez-López, S. Sidana, M. Delforge, L. Pei, D. Trancucci, R. Verona, S. Girgis, S. X. W. Lin, Y. Olyslager, M. Jaffe, C. Uhlar, T. Stephenson, Rian Van Rampelbergh, A. Banerjee, J. Goldberg, R. Kobos, A. Krishnan, S. Usmani   +33 more
semanticscholar   +1 more source

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Survival is poor among patients with triple-class-exposed relapsed and refractory multiple myeloma. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep ...
P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A. Nooka, S. Manier, N. Callander, L. Costa, R. Vij, N. Bahlis, P. Moreau, S. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Zhihong Yang, L. Favre‐Kontula, Fan Wu, J. Piasecki, M. Cook, S. Giralt   +21 more
semanticscholar   +1 more source

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of ...
P. Sonneveld, M. Dimopoulos, M. Boccadoro, Hang Quach, P. J. Ho, M. Beksaç, C. Hulin, Elisabetta Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, Francesca Gay, R. Mina, I. Nijhof, N. W. van de Donk, E. Katodritou, Fredrik H Schjesvold, Anna Sureda Balari, L. Rosiñol, Michel Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, T. Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, E. M. van Brummelen, V. Vanquickelberghe, Anna Sitthi-Amorn, C. D. de Boer, R. Carson, P. Rodríguez-Otero, J. Bladé, P. Moreau   +42 more
semanticscholar   +1 more source

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma

Frontiers in Oncology, 2022
AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei, Jinying Wang, Fei Chen, Xin Li, Jiajia Zhang, Man Shen, Ran Tang, Zhongxia Huang   +7 more
doaj   +1 more source

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

American journal of hematology/oncology, 2022
Multiple myeloma accounts for approximately 10% of hematologic malignancies.
S. Rajkumar
semanticscholar   +1 more source

Multiple Myeloma [PDF]

New England Journal of Medicine, 2011
Multiple myeloma (MM) is a B cell neoplasm of the bone marrow with a complex array of clinical manifestations including anemia, bone lesions, hypercalcemia, renal dysfunction, and compromised immune function. It accounts for 10%–15% of all hematologic malignancies, and 20% of deaths related to cancers of the blood and bone marrow.
PALUMBO, Antonio, Anderson K.
  +8 more sources